21results about How to "Increase drug concentration" patented technology

The invention relates to the field of nano medicines, in particular to a targeted medicine as well as a preparation method and application thereof. The invention provides a targeted drug. The targeted drug comprises a tissue-type plasminogen activator and a targeted peptide. Thrombus targeting modification is directly carried out on a thrombolytic drug rtPA which is most widely applied clinically by utilizing a chemical method, the defects of narrow treatment time window, high dosage and high bleeding risk of the rtPA are remarkably improved, the preparation process is simple and controllable, materials required for preparation are easy to obtain, the cost is low, and the application prospect is wide. The toxic effect and degradation problems of materials such as compounds are eliminated, other instruments and equipment are not needed in the treatment process, and clinical transformation application of thrombus targeted rtPA becomes possible.

This invention relates to the field of biopharmaceutical technology, providing a self-assembled peptide-rhein conjugate, its formulation, preparation method, and applications. The MMP-9-responsive self-assembled peptide-rhein conjugate of this invention, with the sequence Rhein-GFFPLGLAGACE, can respond to abnormally activated MMP-9 in atherosclerotic plaques, self-assembling in situ into a stable nanofiber structure at the lesion site. The rhein in this conjugate exhibits significant anti-inflammatory and antioxidant functions, but its water solubility and oral bioavailability are low. These are significantly improved after conjugation with the peptide, achieving targeted delivery and prolonging retention time. The introduction of the tripeptide ACE, which mimics the function of glutathione, further enhances the conjugate's ability to resist oxidative stress. Furthermore, this conjugate exhibits excellent anti-inflammatory and antioxidant effects, scavenging ROS, inhibiting inflammatory pathways, regulating macrophage phenotype, and inhibiting apoptosis, providing a new strategy for the treatment of atherosclerosis.

The invention discloses enrofloxacin composite nanogel for promoting intestinal absorption and a preparation method of the enrofloxacin composite nanogel. The enrofloxacin composite nanogel comprises 0.1-3% of sodium alginate; 0.1 to 1% of carboxymethyl chitosan; 0.05 to 0.5 percent of mint exosome; and 0.05 to 1 percent of enrofloxacin. According to the composite nanogel disclosed by the invention, the mint exosome and the enrofloxacin are prevented from being damaged by gastric juice through a shell structure of sodium alginate, so that the stability of the mint exosome and the enrofloxacin in the gastric juice is improved; after the enrofloxacin composite nanogel reaches the intestinal tract, the sodium alginate is used as a shell and is subjected to pH responsive swelling hydrolysis, and the wrapped carboxymethyl chitosan-enrofloxacin nanoparticles and the mint exosome are released; the released mint exosome opens close connection of intestinal cells, enrofloxacin is slowly released from carboxymethyl chitosan-enrofloxacin nanoparticles to achieve a slow release effect, and the mint exosome and the enrofloxacin are synergistically targeted to promote absorption of enrofloxacin in intestinal tracts, so that the drug concentration of enrofloxacin in plasma is enhanced.

The invention relates to the technical field of mineral extraction and compound preparation thereof, in particular to a preparation method and application of a nano compound containing a pan jade extract. The method comprises the following steps: S1, crushing and sieving pan jade to obtain pan jade powder, then adding a first solvent, carrying out ultrasonic treatment, centrifuging, taking supernatant liquid, filtering, and carrying out spin-drying, redissolving and vacuum drying on filtrate to obtain pan jade extract; s2, preparing a ZIF-8 nano material from zinc nitrate hexahydrate and 2-methylimidazole; s3, loading the pan jade extract onto the ZIF-8 nano material, so as to obtain ZIF-8 loaded with the pan jade extract; and S4, carrying out functional modification on the ZIF-8 loaded with the pan jade extract by utilizing folic acid to obtain the nano-composite containing the pan jade extract. The nano-composite containing the pan jade extract prepared by the invention is used for resisting tumor proliferation.

The invention provides a bromhexine hydrochloride composition which comprises bromhexine hydrochloride, a cosolvent and a solvent, the content of bromhexine hydrochloride is 1-10w / v%, the content of the cosolvent is 10-50v / v%, and the bromhexine hydrochloride composition further comprises phenol. The bromhexine hydrochloride composition is stable in property and high in solubility, can be mutually soluble with water in any ratio, is simple in production process, is suitable for a bromhexine hydrochloride preparation produced industrially, and achieves the effect through optimization of components and proportions.

The invention particularly relates to a glycosylated dendrimer for co-delivery of small interfering RNA (Ribonucleic Acid) and small molecular drugs as well as a preparation method and application of the glycosylated dendrimer. The nano platform provided by the invention is characterized in that an anti-inflammatory drug resveratrol (Res) and electrostatic adsorption small interfering RNA (si-Cp2e1) are loaded in a glycosylated dendrimer G5-Gal. The preparation method and the application comprise the following steps: preparation of G5-Gal, preparation of Res (at) G5-Gal, and preparation of Res (at) G5-Gal / si-Cp2e1. The preparation method is simple, the required raw materials are easy to obtain, the synthesis process is simple and convenient, separation and purification are easy, and the synthesized nano-drug has a liver targeting capability, can realize dual treatment of small molecule drug-small interfering RNA, and has a potential application prospect in the aspect of treatment of alcohol-related liver diseases.

The invention relates to the technical field of medical instruments, in particular to a photo-initiation medicine balloon catheter which comprises a catheter body, a balloon fixedly arranged at the far end of the catheter body, a catheter base fixedly arranged at the near end of the catheter body and a plurality of micro spraying pipes fixedly arranged on the outer surface of the balloon. Wherein the catheter main body comprises a first catheter, and a second catheter which is fixedly arranged outside the first catheter in a sleeving manner; wherein a first pipe cavity is formed between the inner wall of the second guide pipe and the outer wall of the first guide pipe, and a plurality of second pipe cavities are arranged between the outer wall of the second guide pipe and the inner wall of the second guide pipe in an annular array mode with the axis of the second guide pipe as the reference; through local administration, the photosensitizer is efficiently activated, the side effects of the whole body are reduced, the treatment effect on diseases such as bile duct cancer is improved, the medical cost is reduced, and the living quality of a patient is also improved.

The present application relates to the field of pharmaceutical technology, in particular, to a drug-loaded medical device, including a medical device body and at least one drug coating, the drug coating is attached to at least one side of a surface of the medical device body. The main component of the drug coating includes a macrolide drug. The drug coating includes elongated prismatic crystals each with at least three lateral edges, and / or the drug coating includes crystal clusters of the elongated prismatic crystals each with at least three lateral edges. An aspect ratio of each elongated prismatic crystal is in a range from 1: 1 to 40: 1. The drug-loaded medical device can effectively improve the drug transfer to the blood vessel wall and prolong the concentration of drug in tissue.

The present invention relates to a preparation method and application of an albumin-bound sorafenib nanoformulation chemically modified by MHI-148, comprising the following steps: S1, synthesizing albumin chemically modified by MHI-148 (BSA-MHI148); S2, synthesizing BSA-MHI148@SRF nanoparticles; the albumin-bound sorafenib nanoformulation (BSA-MHI148@SRF) is used for anti-tumor treatment. The albumin-bound sorafenib nanoformulation (BSA-MHI148@SRF) of the present invention can simultaneously solve the problems of tumor hypoxia and high expression of PD-L1.

The invention provides an IAA (Indoleacetic Acid)-PAMAM (Polyamidoamine) G4 nano-composite. The nano-composite is prepared by combining 3-indoleacetic acid and a fourth-generation polyamide-amine type dendrimer together in an ultrasonic manner. The invention further discloses a preparation method of the IAA-PAMAM G4 nano-composite and application of the IAA-PAMAM G4 nano-composite in prevention or treatment of chronic obstructive pulmonary diseases. According to the IAA-PAMAM G4 nano compound disclosed by the invention, the water solubility and the stability of 3-indoleacetic acid are effectively improved, and the anti-inflammatory effect of the 3-indoleacetic acid is enhanced. The IAA-PAMAM G4 nano-composite disclosed by the invention can directly act on the lung in an aerosol inhalation manner, so that the inflammatory response is relieved, and the lung function is improved. In a mouse chronic obstructive pulmonary disease model, a remarkable effect is shown, the pathological change of chronic obstructive pulmonary diseases is relieved, and the lung function is remarkably improved. In addition, the IAA-PAMAM G4 nano-composite also shows an inhibition effect on expression of inflammatory factors in an in-vitro cell experiment, and the cell inflammation level is reduced.

Disclosed are a hydroxypentyl benzoic acid diester compound, a method preparing the same, and an application of the same. This application uses a combination principle, on the one hand, the medicine concentration of butylphthalide in cerebral vessels is improved through a function of promoting the medicine to penetrate through a blood-brain barrier of dexborneol, and a multi-target multi-channel synergistic brain protection effect of the medicine is exerted; on the other hand, the treatment effect of dexborneol on cerebral ischemia is exerted. Anti-cerebral ischemia in-vivo pharmacodynamic activity evaluation is carried out on the synthesized compound, a high-activity candidate medicine is obtained, and industrial production can be achieved through the synthesis method.

This invention discloses a bone repair scaffold material, its preparation method, and its application. The preparation method includes the following steps: preparation of a mineralized collagen core spinning solution; adding mangiferin to a PLGA electrospinning solution and stirring to obtain a shell spinning solution; and using the core spinning solution and the shell spinning solution, obtaining the bone repair scaffold material through coaxial electrospinning. In this invention, PLGA and mangiferin together form the shell of the scaffold structure, and the sustained release of mangiferin provides a guarantee for the anti-inflammatory and angiogenic effects of the scaffold material. Simultaneously, it simulates the fibrous structure of the bone matrix, achieving slow degradation of the core and achieving the goal of long-term promotion of bone repair.

The present application relates to the technical field of pesticides and insecticides, and more particularly to a kind of insecticidal composition containing bromofenac flubendiamide and its application. A kind of insecticidal composition containing bromofenac flubendiamide, by mass fraction, includes the following preparation raw materials: 10-12 parts of insecticide active ingredients, 8-10 parts of emulsifiers, 20-24 parts of penetrants, 0.8-1.2 parts of xanthan gum, 1-3 parts of composite thickeners, 0.2-0.3 parts of antifreeze, 55-60 parts of solvents, wherein the insecticide active ingredients are prepared by mixing bromofenac flubendiamide and emamectin benzoate. The insecticidal composition containing bromofenac flubendiamide provided by the present application has the characteristics of small dosage, low cost and good drug efficacy, which can not only expand the insecticidal spectrum, but also delay pest resistance, and is environmentally friendly, and is a kind of efficient, economical and sustainable agricultural compound insecticide.

The invention provides application of a periorbital injection in preparation of a medicine for treating thyroid eye diseases, and relates to the field of biological medicines. And the periorbital injection contains an anti-IGF-1R (Insulin-like Growth Factor- The periorbital injection provided by the invention has the advantages that the local dosage is small, and the side effect caused by systemic administration can be reduced; the target tissue drug concentration is high, and the effect is strong; the treatment frequency is low, and the patient tolerance is good.

This invention belongs to the field of biomedical technology and relates to an ultrasound-responsive microneedle for acne treatment, specifically a PVDF / curcumin hyaluronic acid microneedle for ultrasound-responsive acne treatment and its preparation method. It is prepared by mixing sodium hyaluronate, PVDF, and curcumin. The PVDF in the microneedle triggers the targeted release of curcumin under ultrasound stimulation, increasing the drug concentration at the lesion site; the antibacterial and anti-inflammatory effects of curcumin synergistically enhance the therapeutic effect of acne treatment with the repair function of hyaluronic acid; the hyaluronic acid matrix reduces skin irritation, making it suitable for long-term use; the preparation process is simple, reproducible, and easy to scale up.

The present invention discloses a chemokine CCL28 immunomodulator for local injection in tissue cell transplantation anti-rejection reaction and its application, wherein the chemokine CCL28 immunomodulator comprises chemokine CCL28 and an adjuvant and / or carrier of chemokine CCL28. The adjuvant and / or carrier is a hydrogel, and the hydrogel comprises methacryloyl gelatin and a photoinitiator, and the concentration is 8-10% W / V of the mass of methacryloyl gelatin / the volume of PBS containing the photoinitiator. The chemokine CCL28 immunomodulator of the present invention can significantly improve the rejection reaction after transplantation by local injection of the transplant in tissue cell transplantation anti-rejection reaction.

The present invention relates to an antibacterial drug-loaded patch for repairing skin and its preparation, belonging to the technical field of medical or cosmetic preparations. The antibacterial drug-loaded patch of the present invention is composed of costus root volatile oil, capillaris extract, hyaluronic acid, glycerol, deionized water, EGCG-pectin complex, backing material, and protective layer. The present invention uses capillaris extract and costus root volatile oil as main drugs to prepare the drug-loaded patch, and verifies the antibacterial ability and skin permeability of the drug-loaded patch, providing a drug-loaded patch with simple ingredients, high safety, and good antibacterial effect.

The invention provides a difunctional polymer nano-carrier system as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical chemicals. The nano carrier system is prepared from the following raw materials: DSPE-PEG-S2P, DSPE-PEG-beta-CD, DSPE-G2K and PLGA (poly (lactic-co-glycolic acid)) through a nano precipitation method. The siTRPM2 is complexed with a cationic lipid carrier DSPE-G2K through electrostatic interaction, the periphery of the cationic lipid is coated with the PLGA based on the hydrophobic interaction between the PLGA and the DSPE-G2K, and the modified targeting peptide S2P and beta-CD are jointly connected to the surface of the carrier. The cationic lipid is stably complexed with siRNA due to positive charges, S2P can rapidly target pro-inflammatory macrophages, modified cyclodextrin (beta-CD) can include, dissolve and remove cholesterol in atherosclerotic plaques and promote cholesterol excretion, and the carrier system has a good effect in silencing TRPM2 and CD36 proteins, and can be used for preparing an anti-inflammatory drug for treating atherosclerotic plaques. And intervention treatment can be performed on formation and development of plaques in a lesion area at the same time.

The present invention relates to the field of biomedicine technology, and in particular to a deuterated molecular glue that can selectively induce the formation of a type 3A phosphodiesterase (PDE3A) and SLFN12 complex and apoptosis of tumor cells, a preparation method thereof, and an application thereof in tumor treatment.

The invention belongs to the technical field of pharmaceutical preparations, and particularly provides a salinomycin derivative sal-098 targeted liposome as well as a preparation method and application thereof. The membrane is prepared from a membrane material, a long circulating substance, a stabilizer, a salinomycin derivative and a tumor targeting substance through a membrane hydration method. The salinomycin derivative targeted liposome disclosed by the invention can target colorectal cancer tissues, more efficiently kill tumor cells and reduce the toxicity of salinomycin derivatives at the same time.

The application relates to a preparation and application of an FXI targeting siRNA molecule and a GalNAC conjugate thereof. The siRNA molecule takes TN7 sequence as a core, is obtained through precise bioinformatics design and high-throughput screening, and has excellent gene silencing activity. Through systematic chemical modification optimization, the stability of the molecule is significantly improved. More importantly, the TN7-GalNAC conjugate exhibits an unprecedented persistent inhibitory effect in a mouse in-vivo experiment, and the FXI protein level is maintained below 10% of the basic level within 28 days after single administration. The application provides a new molecular tool for precise treatment of thrombotic diseases, and has important clinical application value.